Caliper Life Sciences reports expanded sales of its LabChip and Ivis drug discovery and development systems to top-tier customers including Pfizer, AstraZeneca, and Momenta Pharmaceuticals
These systems help scientists accelerate and improve drug discovery and development.
Caliper's LabChip and Ivis systems connect research data from in vitro experimentation (outside a living organism) to in vivo experimentation (inside a living organism), while providing the highest precision, efficiency and quality of data.
By connecting in vivo and in vitro experimentation, researchers are better able to predict human outcomes and reduce drug candidate attrition.
Caliper's portfolio of offerings provides the pharmaceutical industry with the technology and support to improve clinical relevance and more rapidly develop effective treatments for disease.
"With the Caliper name supporting the Ivis imaging system, we are seeing rapid adoption in the commercial sector," said Kevin Hrusovsky, CEO of Caliper Life Sciences.
"The sales of both products are representative of Caliper's ability to meet the needs and demands of the industry while fostering the company's own growth and strategic direction as a leading provider of in vitro and in vivo drug discovery and development technologies."
